Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib

Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib

The availability of targeted therapies for molecular aberrations have substantially improved the outcomes of advanced non-small-cell lung cancer (NSCLC) patients harboring sensitive mutations. However, patients harboring uncommon epidermal growth factor receptor (EGFR) mutations such as G719X and L8...

Full description

Bibliographic Details
Main Authors:	Zihan Zhou, Jie Huang, Ming Ding, Jing Huang, Ting Wu, Qun Wang, Shuhua Han, Yuan Lu
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Respiratory Medicine Case Reports
Subjects:	Epidermal growth factor receptor (EGFR) Non-small cell lung cancer (NSCLC) Afatinib L861Q G719X Compound mutations
Online Access:	http://www.sciencedirect.com/science/article/pii/S221300712300148X

Similar Items

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
by: Wei Dong, et al.
Published: (2022-11-01)

Corrigendum: Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
by: Chunhua Ma, et al.
Published: (2019-09-01)

Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low‐dose afatinib: A case report
by: Yuko Iida, et al.
Published: (2020-02-01)

Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature
by: Lin Li
Published: (2022-09-01)

Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review
by: Yun Zhao, et al.
Published: (2023-02-01)

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
by: Jing Liu, et al.
Published: (2019-07-01)

Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
by: Alexander Meisel
Published: (2020-03-01)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
by: Keunchil Park, MD, PhD, et al.
Published: (2021-09-01)

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer
by: Kazumi Sano, et al.
Published: (2020-04-01)

Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation
by: Chih-Hsi Scott Kuo, et al.
Published: (2022-01-01)

Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations
by: Giuseppe Pompilio, et al.
Published: (2022-01-01)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
by: Junyan Tao, et al.
Published: (2020-09-01)

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study
by: E. A. van de Stadt, et al.
Published: (2020-08-01)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
by: Yingying Jiang, et al.
Published: (2023-05-01)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR‐mutated NSCLC treated with afatinib
by: Chen‐Te Wu, et al.
Published: (2023-09-01)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
by: Yuko Oya, et al.
Published: (2021-01-01)

Second-line afatinib administration in an elderly patient with squamous cell carcinoma
by: Hohenforst-Schmidt W, et al.
Published: (2017-03-01)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
by: Liping Kang, et al.
Published: (2023-02-01)

Role of afatinib in the treatment of advanced lung squamous cell carcinoma
by: Vavalà T
Published: (2017-11-01)

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
by: Wen-Chien Cheng, et al.
Published: (2024-02-01)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
by: Antonio Passaro, et al.
Published: (2021-07-01)

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
by: Gwo-Fuang Ho, et al.
Published: (2019-09-01)

Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a case report
by: Zhedong Zhang, et al.
Published: (2024-04-01)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
by: Jingran Ji, MD, et al.
Published: (2023-03-01)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
by: Yang Wei, MD, et al.
Published: (2021-07-01)

TARGETED THERAPY OF NSCLC WITH EGFR ACTIVATING MUTATIONS IMPROVES THE QUALITY OF LIFE OF PATIENTS
by: T. Y. SEMIGLAZOVA, et al.
Published: (2016-12-01)

Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
by: German E. Ramos, et al.
Published: (2022-11-01)

Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report
by: Xingxing WANG, et al.
Published: (2015-09-01)

Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group
by: Sara Agraso, et al.
Published: (2022-01-01)

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
by: Yue Hao, et al.
Published: (2023-08-01)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
by: Keunchil Park, et al.
Published: (2021-07-01)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
by: Akiko Takahashi, et al.
Published: (2018-10-01)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
by: Tomomi Masuda, et al.
Published: (2020-08-01)

Molecularly Targeted Photothermal Ablation of Epidermal Growth Factor Receptor-Expressing Cancer Cells with a Polypyrrole–Iron Oxide–Afatinib Nanocomposite
by: Lekshmi Rethi, et al.
Published: (2022-10-01)

Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
by: Naoki Shijubou, et al.
Published: (2021-03-01)

Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I
by: Seigo Minami, et al.
Published: (2019-02-01)

Afatinib: new treatment options for lung cancer with activating EGFR mutations
by: M. V. Stepanchenko, et al.
Published: (2015-12-01)

In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
by: Xue C, et al.
Published: (2016-03-01)

A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review
by: Yu Wei, et al.
Published: (2021-06-01)

Uncommon <i>EGFR</i> Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
by: Ilaria Attili, et al.
Published: (2022-01-01)